Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026)
Bio-Techne's quarterly Current Deferred Revenue came in at $40.7 million in Q1 2026, up 26.13% year-on-year from $32.3 million in Q1 2025, and up 31.16% quarter-over-quarter from $31.0 million in Q4 2025.
Bio-Techne has reported Current Deferred Revenue for 13 years, with the latest figure at $40.7 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 26.13% year-over-year to $40.7 million; the trailing twelve-month figure through Mar 2026 stood at $40.7 million (up 26.13% YoY), and the FY2025 full-year result was $35.3 million, up 26.39% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $40.7 million, up from $31.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $40.7 million in Q1 2026, with the low at $23.1 million in Q1 2022.
- Average Current Deferred Revenue over 5 years is $28.7 million, with a median of $27.9 million recorded in 2024.
- Year-over-year, Current Deferred Revenue increased 28.09% in 2023 and declined 7.92% in 2024.
- Tracing TECH's Current Deferred Revenue over 5 years: stood at $23.5 million in 2022, then climbed by 28.09% to $30.1 million in 2023, then slipped by 7.92% to $27.7 million in 2024, then gained by 11.96% to $31.0 million in 2025, then surged by 31.16% to $40.7 million in 2026.
- The last three Current Deferred Revenue figures came in at $40.7 million (Q1 2026), $31.0 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.70 Mn |
| Dec 31, 2025 | 31.03 Mn |
| Sep 30, 2025 | 30.45 Mn |
| Jun 30, 2025 | 35.30 Mn |
| Mar 31, 2025 | 32.27 Mn |
| Dec 31, 2024 | 27.72 Mn |
| Sep 30, 2024 | 29.20 Mn |
| Jun 30, 2024 | 27.93 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | 30.10 Mn |
| Sep 30, 2023 | 25.80 Mn |
| Jun 30, 2023 | 24.60 Mn |
| Mar 31, 2023 | 26.50 Mn |
| Dec 31, 2022 | 23.50 Mn |
| Sep 30, 2022 | 24.00 Mn |
| Jun 30, 2022 | 23.41 Mn |
| Mar 31, 2022 | 23.11 Mn |
| Dec 31, 2021 | 19.08 Mn |
| Sep 30, 2021 | 19.12 Mn |
| Jun 30, 2021 | 20.00 Mn |
| Mar 31, 2021 | 19.70 Mn |
| Dec 31, 2020 | 13.22 Mn |
| Sep 30, 2020 | 13.40 Mn |
| Jun 30, 2020 | 14.20 Mn |
| Mar 31, 2020 | 14.80 Mn |
| Dec 31, 2019 | 11.89 Mn |
| Sep 30, 2019 | 9.11 Mn |
| Jun 30, 2019 | 9.08 Mn |
| Mar 31, 2019 | 10.11 Mn |
| Dec 31, 2018 | 8.40 Mn |
| Sep 30, 2018 | 10.60 Mn |
| Jun 30, 2018 | 8.11 Mn |
| Mar 31, 2018 | 7.84 Mn |
| Dec 31, 2017 | 6.02 Mn |
| Sep 30, 2017 | 5.37 Mn |
| Jun 30, 2017 | 5.97 Mn |
| Mar 31, 2017 | 6.07 Mn |
| Dec 31, 2016 | 4.85 Mn |
| Sep 30, 2016 | 4.48 Mn |
| Jun 30, 2016 | 4.72 Mn |
| Mar 31, 2016 | 5.22 Mn |
| Dec 31, 2015 | 3.14 Mn |
| Sep 30, 2015 | 3.84 Mn |
| Jun 30, 2015 | 3.38 Mn |
| Mar 31, 2015 | 3.49 Mn |
| Dec 31, 2014 | 2.81 Mn |
| Sep 30, 2014 | 2.55 Mn |